21
Participants
Start Date
January 31, 2010
Primary Completion Date
April 30, 2014
Study Completion Date
July 31, 2014
Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan
Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
The Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
The University of North Carolina at Chapel Hill, Chapel Hill
Duke University, Durham
Emory University, Atlanta
University of Miami, Miami
All Children's Research Institute, Inc., St. Petersburg
Vanderbilt University, Nashville
The Research Institute at Nationwide Children's Hospital, Columbus
University of Michigan, Ann Arbor
Children's Memorial Hospital, Chicago
Washington University, St Louis
UT Southwestern Medical Center, Dallas
Methodist Healthcare System of San Antonio, San Antonio
Regents of University of California- UCLA, Los Angeles
Children's Hospital and Research Center at Oakland, Oakland
Oregon Health and Science University, Portland
Dana Farber Cancer Institute, Boston
Collaborators (1)
Carelon Research
OTHER
Pediatric Blood and Marrow Transplant Consortium
OTHER
Washington University School of Medicine
OTHER